Leerink Partners analyst Thomas Smith has maintained their bullish stance on TRML stock, giving a Buy rating on March 14.
Thomas Smith has given his Buy rating due to a combination of factors surrounding Tourmaline Bio’s promising developments. The company’s lead program, pacibekitug, is advancing in its clinical trials, with significant anticipation for the Phase 2 TRANQUILITY trial results in atherosclerotic cardiovascular disease (ASCVD) expected in the second quarter of 2025. This trial is crucial as it could position pacibekitug for Phase 3 readiness, especially if it demonstrates a strong balance between efficacy and safety.
Additionally, the TRANQUILITY trial outcomes are expected to have implications for pacibekitug’s development in other indications such as abdominal aortic aneurysm (AAA) and thyroid eye disease (TED). The potential for pacibekitug to address these conditions, coupled with its competitive dosing schedule, underscores its strategic value. These factors collectively contribute to the positive outlook and the Buy rating assigned by Thomas Smith.
According to TipRanks, Smith is a top 100 analyst with an average return of 35.9% and a 48.03% success rate. Smith covers the Healthcare sector, focusing on stocks such as Celldex, Cartesian Therapeutics, and Viridian Therapeutics.